M&A / Deals Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact Pharmaceutical TechnologyEli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing.Read full story pharminent April 29, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Eli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing. Read full story Post navigation Previous: The strategic investments expanding CDMO capabilities for HPAPIs and ADCsNext: Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’ Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026